Proprietary Technology
The Mirai™ Platform
A patented capsule-based inhaler - device IP granted in the United States and 38 European countries - designed for improved patient compliance, broad therapeutic application, and lower cost to healthcare systems.
Designed for Patients, Built for Performance
The Mirai™ inhaler represents a new approach to capsule-based dry powder inhalation. Our global design addresses the key limitations of existing devices while maintaining the established reliability of capsule delivery.
Granted Patent Protection
Device patents granted in the US and 38 European countries - one design for global markets, simplifying regulatory pathways and reducing costs.
Low Resistance
Designed for patients with limited inspiratory capacity - elderly COPD patients and pediatric populations.
Designed for Lower Cost
Efficient design and a manufacturing partnership are intended to deliver meaningful cost advantages.
Modern, Patient-Friendly Design
Sleek, pocket-sized form factor designed to encourage everyday use and support compliance.
The Mirai™ Difference
Every capsule inhaler on the market relies on piercing or cutting the capsule. We engineered a fundamentally different approach.
The Mirai™ Approach
- Pulls capsule apart - no piercing
Capsule separates cleanly, eliminating particulate risk entirely
- Stationary capsule = consistent dosing
Capsule remains fixed during inhalation - predictable, uniform delivery
- 100% plastic - fully washable
No metal components means easy cleaning and extended reusability
Traditional Capsule Inhalers
- Piercing creates particulates
Metal pins puncture capsules, creating fragments that patients may inadvertently inhale
- Spinning capsule = inconsistent dosing
Capsule spins during inhalation - delivery varies based on inspiratory force
- Steel components limit durability
Metal parts prevent washing, limiting reusability and hygiene
Device Specifications
Inhaler Type
Passive (no electronics), capsule-based DPI
Capsule Compatibility
Multi-size (size 0 and size 3)
Airflow Resistance
Low resistance design for consistent dosing
Capsule Mechanism
Pull-apart release - no piercing, stationary during inhalation
Materials
100% plastic (ABS + PC) - no metal, fully washable
Form Factor
Pocket-sized, modern design
Patent Status
Granted - United States + 38 European countries
The Integrated Advantage
Unlike competitors who specialize in either devices or formulations, Knightpoint Group controls both - enabling optimized system performance for combination products.
Device Expertise
- Patented inhaler design
- Global manufacturing partnership
- Device performance optimization
Formulation Science
- Triple-combination expertise
- ICS/LAMA/LABA programs
- ICS/LAMA/LABA formulation know-how
Broad Therapeutic Potential
The Mirai™ platform is designed for diverse therapeutic applications beyond traditional respiratory.
Respiratory
COPD, asthma, and other chronic respiratory conditions with proven capsule-based delivery.
Biologics
Emerging inhaled biologics for systemic and local delivery applications.
Oncology
Targeted pulmonary delivery for lung cancer and other oncology applications.
Interested in Licensing?
The Mirai™ device platform - with granted IP in the United States and 38 European countries - is available for licensing or acquisition. Contact our business development team.
Contact Us